PALI Palisade Bio Inc.

Biotech Analyst Ratings

Latest News

1. 13 May 2022 Palisade Bio Reports First Quarter 2022 Financial Results and Provides Corporate Update

   Phase 3 study of LB1148 in lead indication for postoperative return of bowel function on track to commence Q2 2022
   

   Ongoing Phase 2 study of LB1148 for the prevention of post-surgical abdominal adhesions
   

   CARLSBAD, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (NASDAQ:PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today reported its financial results for the quarter ended March 31, 2022.

   Additionally, the Company provided a clinical program update for its lead asset in development, LB1148, an oral formulation of a broad-spectrum serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during…

   View Full Article
2. 06 May 2022 Palisade Bio Announces $2.0 Million Registered Direct Offering

   CARLSBAD, Calif., May 06, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) (the "Company" or "Palisade Bio"), a clinical-stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal complications, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale in a registered direct offering of 3,646,690 shares of its common stock, at a purchase price of $0.55 per share.
   

   Ladenburg Thalmann & Co. Inc. is acting as the exclusive placement agent for the offering.

   The closings of the sale of the securities in the financing is expected to occur on or about May 10, 2022, subject to the satisfaction of customary closing conditions…

   View Full Article
3. 05 May 2022 Palisade Bio and Newsoara Receive NMPA Clearance to Commence Phase 3 Clinical Trial in China Evaluating LB1148 to Accelerate the Return of Bowel Function Following Abdominal Surgery

   NMPA clearance expands global Phase 3 clinical development program; Company recently announced clearance from U.S. Food and Drug Administration to commence Phase 3 study
   

   Newsoara to fully fund Phase 3 program in China

   Under the Co-Development Agreement, commencement of Phase 3 program in China will trigger milestone payment to Palisade Bio

   CARLSBAD, Calif. and SHANGHAI, China, May 05, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (NASDAQ:PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications and co-development partner Newsoara Biopharma Co. Ltd, today announced they have received clearance from the National Medical Products Administration (NMPA) in China to proceed with their…

   View Full Article
4. 02 May 2022 Palisade Bio Provides Business Outlook and Highlights Expected Near-Term Pipeline Advancements

   CARLSBAD, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (NASDAQ:PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today provided a business outlook and outlined its expected near-term pipeline advancements.
   

   "The positive data we have amassed continues to support our development strategy and provides us with confidence as we advance our lead program into a Phase 3 study this quarter. Each day that a patient remains in the hospital can cost upwards of approximately $2,400, representing a significant burden on the cost of healthcare. We believe, if approved, LB1148 will protect gastrointestinal integrity and accelerate the return of postoperative GI function…

   View Full Article
5. 29 April 2022 Palisade Bio to Participate in the Virtual Investor Management and KOL Roundtable Event

   CARLSBAD, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (NASDAQ:PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that members of management will participate in the Virtual Investor Management and KOL Roundtable Event on Tuesday, May 3, 2022 at 10:00 AM ET.
   

   Participating from the Palisade Bio management team will be Tom Hallam, Ph.D., Chief Executive Officer, Michael Dawson, M.D., Chief Medical Officer and Robert McRae, Senior Vice President, Operations and Strategic Development.

   Joining Palisade Bio management will be Key Opinion Leader, David B. Hoyt, MD, FACS, MAMSE. Dr. Hoyt is the Executive Director of the American College…

   View Full Article